Kirchner Group Advises Investor in $230M Financing in the BioTech Sector
Kirchner Group is pleased to announce that it acted as an advisor on due diligence to the Alaska Permanent Fund in the recently announced Tessera Therapeutics $230M Series B financing.
Read Article